ASCO 2022 | Exploratory analyses from JAVELIN Bladder 100
Joaquim Bellmunt, MD, PhD, Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, discusses results from the JAVELIN Bladder 100 trial (NCT02603432) which investigated avelumab maintenance therapy for patients with metastatic or locally advanced bladder cancer. 60% of patients in the trial received a subsequent therapy after progression on avelumab maintenance, including chemotherapy, immunotherapy, and antibody-drug conjugates. This post-hoc analysis of the trial reported that the survival benefit of avelumab maintenance therapy was observed in patients regardless of which subsequent treatment they received. However, further research with larger cohorts is needed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
